Literature DB >> 31261173

The role of genetics in the pathogenesis and diagnosis of type 1 Von Willebrand disease.

Veronica H Flood1,2,3, Jessica Garcia4, Sandra L Haberichter1,2,3.   

Abstract

PURPOSE OF REVIEW: Von Willebrand disease (VWD) is a common bleeding disorder, but diagnosis of VWD is challenging, particularly with type 1 VWD. Although most clinicians use specific tests of von Willebrand factor (VWF) activity to classify patients with VWD, genetic testing for VWF defects is another potential method of diagnosis. RECENT
FINDINGS: Studies of patients with type 1 VWD report consistently that many, but not all, study participants have VWF gene defects. Certain populations, including those with VWF levels less than 30 IU/dl and those with clearance defects, are more likely to have a VWF sequence variant. In addition, a number of loci outside the VWF gene have been shown to affect VWF levels, including ABO, CLEC4M, STXBP5, and STAB2.
SUMMARY: Genetic defects in VWF are common, but not all defects lead to disease. Type 1 VWD in particular does not always have an associated VWF sequence variant. New data stemming from genome-wide association studies on modifier genes suggest that the etiology of type 1 VWD is multifactorial.

Entities:  

Year:  2019        PMID: 31261173      PMCID: PMC6727843          DOI: 10.1097/MOH.0000000000000524

Source DB:  PubMed          Journal:  Curr Opin Hematol        ISSN: 1065-6251            Impact factor:   3.284


  44 in total

1.  The mutational spectrum of type 1 von Willebrand disease: Results from a Canadian cohort study.

Authors:  Paula D James; Colleen Notley; Carol Hegadorn; Jayne Leggo; Angie Tuttle; Shawn Tinlin; Christine Brown; Chandler Andrews; Andrea Labelle; Yvette Chirinian; Lee O'Brien; Maha Othman; Georges Rivard; Dilys Rapson; Christine Hough; David Lillicrap
Journal:  Blood       Date:  2007-01-01       Impact factor: 22.113

Review 2.  Von Willebrand disease type 1: a diagnosis in search of a disease.

Authors:  J Evan Sadler
Journal:  Blood       Date:  2002-10-31       Impact factor: 22.113

3.  Assay of the von Willebrand factor (VWF) propeptide to identify patients with type 1 von Willebrand disease with decreased VWF survival.

Authors:  Sandra L Haberichter; Michael Balistreri; Pamela Christopherson; Patricia Morateck; Stefana Gavazova; Daniel B Bellissimo; Marilyn J Manco-Johnson; Joan Cox Gill; Robert R Montgomery
Journal:  Blood       Date:  2006-07-11       Impact factor: 22.113

4.  Phenotype and genotype of a cohort of families historically diagnosed with type 1 von Willebrand disease in the European study, Molecular and Clinical Markers for the Diagnosis and Management of Type 1 von Willebrand Disease (MCMDM-1VWD).

Authors:  Anne Goodeve; Jeroen Eikenboom; Giancarlo Castaman; Francesco Rodeghiero; Augusto B Federici; Javier Batlle; Dominique Meyer; Claudine Mazurier; Jenny Goudemand; Reinhard Schneppenheim; Ulrich Budde; Jorgen Ingerslev; David Habart; Zdena Vorlova; Lars Holmberg; Stefan Lethagen; John Pasi; Frank Hill; Mohammad Hashemi Soteh; Luciano Baronciani; Christer Hallden; Andrea Guilliatt; Will Lester; Ian Peake
Journal:  Blood       Date:  2006-09-19       Impact factor: 22.113

5.  A reliable and reproducible ELISA method to measure ristocetin cofactor activity of von Willebrand factor.

Authors:  K Vanhoorelbeke; N Cauwenberghs; S Vauterin; A Schlammadinger; C Mazurier; H Deckmyn
Journal:  Thromb Haemost       Date:  2000-01       Impact factor: 5.249

6.  An investigation of the von Willebrand factor genotype in UK patients diagnosed to have type 1 von Willebrand disease.

Authors:  Anthony Cumming; Pamela Grundy; Stephen Keeney; William Lester; Said Enayat; Andrea Guilliatt; Derrick Bowen; John Pasi; David Keeling; Frank Hill; Paula H B Bolton-Maggs; Charles Hay; Peter Collins
Journal:  Thromb Haemost       Date:  2006-11       Impact factor: 5.249

7.  Laboratory tests for measurement of von Willebrand factor show poor agreement among different centers: results from the United Kingdom National External Quality Assessment Scheme for Blood Coagulation.

Authors:  Steve Kitchen; Ion Jennings; Tim A L Woods; Dianne P Kitchen; Isobel D Walker; Francis E Preston
Journal:  Semin Thromb Hemost       Date:  2006-07       Impact factor: 4.180

8.  An external quality assessment program for von Willebrand factor laboratory analysis: an overview from the European concerted action on thrombosis and disabilities foundation.

Authors:  Piet Meijer; Frits Haverkate
Journal:  Semin Thromb Hemost       Date:  2006-07       Impact factor: 4.180

Review 9.  von Willebrand factor: two sides of a coin.

Authors:  J E Sadler
Journal:  J Thromb Haemost       Date:  2005-08       Impact factor: 5.824

10.  von Willebrand disease (VWD): evidence-based diagnosis and management guidelines, the National Heart, Lung, and Blood Institute (NHLBI) Expert Panel report (USA).

Authors:  W L Nichols; M B Hultin; A H James; M J Manco-Johnson; R R Montgomery; T L Ortel; M E Rick; J E Sadler; M Weinstein; B P Yawn
Journal:  Haemophilia       Date:  2008-03       Impact factor: 4.287

View more
  1 in total

Review 1.  The Vascular Endothelium and Coagulation: Homeostasis, Disease, and Treatment, with a Focus on the Von Willebrand Factor and Factors VIII and V.

Authors:  Juan A De Pablo-Moreno; Luis Javier Serrano; Luis Revuelta; María José Sánchez; Antonio Liras
Journal:  Int J Mol Sci       Date:  2022-07-27       Impact factor: 6.208

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.